NCT05781048 2026-03-10
A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
Jiangsu HengRui Medicine Co., Ltd.
BeOne Medicines
Genmab
Ganzhou Hemay Pharmaceutical Co., Ltd
Quanta Therapeutics
BioGate Precision Medicine Corp.
Debiopharm International SA
Hangzhou Converd Co., Ltd.
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Amgen